Celyad has struck a deal with Ono Pharmaceutical for certain rights to its allogeneic NKR-2 T-cell immunotherapy, a variation on traditional CAR-T approaches. The agreement eases some of the pressure from the recent late stage failure of Celyad's heart failure cell therapy.

HIV drug Tivicay is expected to become cheaper in China under a recent manufacturing deal between ViiV and Desano. The Chinese firm expects to gain a 35% share of the global generic antiretroviral API supply market this year after patent licensing agreements with the Medicines Patent Pool.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014-January 2015.

Among the 113 listed pharma in China, more than two thirds reported sales growth in the first three quarters of the year.